Niagen Bioscience (NASDAQ:NAGE) Issues Earnings Results

Niagen Bioscience (NASDAQ:NAGE) released its quarterly earnings results on Tuesday. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03, Zacks reports. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Niagen Bioscience Stock Down 3.9%

Shares of NASDAQ NAGE traded down $0.28 during midday trading on Tuesday, hitting $6.95. The stock had a trading volume of 1,078,639 shares, compared to its average volume of 975,393. The company has a market capitalization of $554.28 million, a PE ratio of 33.10 and a beta of 2.13. The stock has a 50 day simple moving average of $8.60 and a 200-day simple moving average of $9.70. Niagen Bioscience has a 1 year low of $5.16 and a 1 year high of $14.69.

Analyst Ratings Changes

NAGE has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Wednesday, October 8th. HC Wainwright increased their price objective on Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, August 11th. Finally, Wall Street Zen lowered Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Niagen Bioscience has a consensus rating of “Moderate Buy” and an average price target of $13.42.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.